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Background: ‘Chemsex’ is the use of drugs before or during planned sexual events 
to facilitate, enhance, prolong and sustain the experience. Drugs associated with 
chemsex are methamphetamine, GHB/GBL, mephedrone, cocaine and ketamine. 
This review syntheses published research on the antecedents, behaviours and 
consequences associated with chemsex behaviours among men who have sex with 
men (MSM).        
 
Methods:  Papers from high income countries which were published between January 
2000 and September 2018 reporting the use of chemsex drugs before or during sex 
were identified through Medline, Web of Science, CINAHL and Central.  Results were 
synthesised using a narrative approach and conceptualised using a behavioural 
analysis framework.    
 
Results: The search identified 2492 publications, of which 38 were included in the 
final synthesis.  There were wide variations in chemsex prevalence estimates due to 
the heterogeneous sampling in the studies.   Chemsex participants have expectations 
that the drugs will positively affect their sexual encounters and HIV positive MSM are 
more likely to engage in the behaviour than HIV negative MSM.  There were wide 
ranging prevalence estimates on injecting drugs for sexual purposes and the sharing 
of injecting equipment with some evidence of unsafe injecting practices.  Participants 
were more likely to engage in condomless anal intercourse than men who do not 
engage in chemsex.  This may increase the risk of transmission for HIV and other 
sexually transmitted infections.   
 
Conclusion: A minority of MSM appear to engage in chemsex behaviours but they 
are at risk of this negatively impacting on their health and well-being.  Further research 
is required to examine high risk chemsex behaviours, impact of chemsex on psycho-
social well-being and if chemsex influences uptake of PrEP, PEP and sexual health 
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Men who have sex with men (MSM) can have significant and multi-faceted 
relationships with drugs and alcohol. Public Health England ([PHE], 2014) identify an 
alcohol dependence rate among MSM that is double that of the non-MSM male 
population. The Office for National Statistics ([ONS], 2014) report gay and bisexual 
men to be three times more likely to use illicit substances than their heterosexual 
counterparts. One quarter of a sample of MSM drawn from twenty sexual health clinics 
in England report using three or more recreational drugs in the previous three months 
(Sewell et al, 2017). However, sexual health clinic samples are likely to provide over-
estimates for substance use behaviours and differences would also be expected 
between metropolitan samples of MSM and country-wide estimates. However, poly 
drug use is a recognised concern among MSM particularly those who use drugs before 
or during sex.  
 
Sexualised drug use (SDU) refers to the use of any illicit drug just before or during sex 
and a subset term of SDU is referred to as ‘chemsex’ (Edmundson et al, 2018). 
Chemsex behaviours are described as the use of specific drugs before or during 
planned sex to facilitate, initiate, prolong, sustain and intensify the encounter (PHE, 
2015; Bourne et al, 2015). Certain drugs have been associated with chemsex 
behaviours including mephedrone, methamphetamine, and GHB/GBL (Gamma 
hydroxybutyrate/Gamma butyrolactone) (PHE, 2015). In a London based study 
cocaine and ketamine were also linked to the behaviours (Bourne et al, 2014).  A high-
risk behaviour associated with chemsex involves the injecting of a drug for sexual 
purposes (PHE, 2015).  The concept of ‘chemsex’ is socially constructed and as such 
is subject to the preferences of participants and the popularity and availability of 
specific drugs. Furthermore, these features are likely to vary across countries and 
among sub-cultures within countries, as well as across time. 
 
There have been growing concerns about the interconnected nature of high risk 
drug/sexual behaviours and the increased transmission risk of blood borne viruses 
(BBV) and sexually transmitted infections (STIs) (PHE, 2015).  In the United Kingdom 
(UK) MSM account for more than half of all new human immunodeficiency virus (HIV) 
infections which demonstrates that they are disproportionately affected by the disease 
in comparison to the general population (PHE, 2016). The advent of HIV antiretroviral 
therapy and pre-exposure prophylaxis (PrEP) provide protection by reducing the risk 
of onward transmission and acquisition. However, the effectiveness of these 
medicines is reliant on patient adherence and there is limited evidence on the impact 
of chemsex behaviours on medication adherence.  In addition to the biological risk, 
there is increasing concerns that chemsex may be associated with psychosocial risks. 
Tomkins et al (2018) identified that there is growing evidence which indicates that 
chemsex is potentially associated with the mental ill health of MSM who engage in the 
activity. This highlights that there are potentially multiple biopsychosocial risk factors 
for MSM that engage in chemsex behaviours.   
 
Chemsex has attracted international clinical and research attention from which there 
is an emerging body of knowledge on different aspects of the behaviour. For example, 
its prevalence (Heiligenberg et al, 2012), sociodemographic characteristics associated 
with the behaviour (Obera et al, 2009), patterns of drug use and sexual behaviours 
(Benotsch et al. 2012), biopsychosocial impact of the behaviour (Hegazi et al, 2017), 
and associations with HIV (Bourne et al, 2015).  In early 2018 two published literature 
reviews (Edmundson et al, 2018; Tomkins et al, 2018) examined some aspects of 
chemsex but had a wider focus on MSM sexualised drug use. To date, we are not 
aware of a literature review that has specifically examined the research related to 
chemsex drug use before or during sex.  As chemsex participants health is potentially 
at high-risk there is a need to systematically interrogate the literature on chemsex drug 
use within a sexualised setting.  This review will comprehensively analysis the 
behaviours involved in chemsex activities, including the risks they present to 
participants.  The review will help inform the development of evidence-based risk 




The research team anticipated that different methods and means of measurement 
would characterise the literature in the emerging evidence base on chemsex 
behaviours.  This review was conducted as a narrative review, guided by a conceptual 
framework and drawing on systematic methodology as far as possible to promote 
transparency and replicability with results reported according to PRISMA guidelines 
(Liberati et al., 2009). 
 
Chemsex behaviours are activities for which the antecedent-behaviour-consequence 
(ABC) framework provides a useful way to map potential variables of interest. Table 1 
contains a provisional ABC analysis of chemsex drawn from the literature and from 
research team discussions.  It provides a framework to organise review findings and 
to specify the review’s objectives:  
 
1. To establish prevalence estimates for chemsex behaviour among MSM;  
2. To document chemsex behaviour in terms of drugs used, high risk drug use 
behaviour, sexual risk behaviour and characteristics of the drug use setting;  
3. To gauge whether sex sessions that include drugs differ from those that do not 
in terms of the behaviours and associated risks; 
4. To identify factors associated with chemsex behaviour, including HIV status, 
individual’s socio-demographics and expectations of participation; 
5. To identify any bio-medical risk reduction interventions used by chemsex 
participants and whether their use is compromised when drugs are combined 
with sex; 
6. To identify the biopsychosocial impact of chemsex behaviour on participants, 
including risk of STI/BBV infection and the psychosocial impact.  
 
There are challenges to identifying and reaching representative populations of MSM 
who engage in chemsex behaviours. Added to this are the challenges of classifying 
and measuring a varied, uncommon set of human behaviours. The sampling frames 
of the studies included in this review will by extension be heterogeneous and not 
representative, making accurate population estimates unrealistic. For example, where 
studies have recruited samples from sexual health or drug treatment services, 
prevalence is likely to be over-estimated. The context for each study and its potential 
effects on prevalence are addressed when estimates are presented in the review. 
 
Table 1:  ABC analysis of chemsex behaviour between MSM 
 
Antecedent Behaviour Consequence 
• Sociodemographic 
characteristics 
• HIV status 
• Expectations of the event 
 
• Prevalence 
• Drugs used 
• Injecting drug use 
• Drug use setting 
• Sexual behaviours 
• Bio-medical risk reduction 
interventions 
• Physical including 
HIV/BBV/STI infection 
• Psychological 






This review includes studies of chemsex behaviours that involve drug use before or 
during sex with any one of the following drugs: methamphetamine, mephedrone, 
GHB/GBL, cocaine and ketamine. To be able to consider HIV risk reduction strategies 
during chemsex behaviours, alongside other potential biopsychosocial harms and 
protective mechanisms, studies were included that sampled HIV negative MSM or 
those whose HIV status was unknown. Studies that exclusively sampled HIV positive 
MSM were excluded. The review includes studies of primary research from high 
income countries, as defined by the World Bank, which were published in peer review 
journals in the English language between1st of January 2000 and 1st of September 
2018.   
   
Information sources and search 
 
Four databases were used for the search; Medline, CINAHL, Web of Science and 
CENTRAL. The databases were selected to reflect medical, nursing, allied health 
professionals, sociological and clinical trial journals.  Table 2 presents the MESH terms 
and key words that were used for the search. One reviewer conducted the search 
using a predefined protocol which was developed in combination with another two 
senior researchers. The search was conducted initially in December 2017 and was 
updated in September 2018. 
 
Table 2: PIO search terms 
 
Population Intervention  Outcome 
Men who have sex with men 
(MSM) 
Chemsex Sexually transmitted infection(s) 
Homosexual me(a)n Party and play Sexually transmitted disease(s) 
Gay me(a)n Sexualised drug use HIV 
Gay male(s) Slamming Hepatitis C 
 Substance use disorder(s)   




Data retrieved through the search were extracted onto Endnote x8 (Thomson Reuters, 
New York, USA).  At the abstract stage an independent reviewer examined a random 
sample of abstracts (10% of those excluded and 20% of those included) to ensure the 
robust application of the inclusion and exclusion criteria. A third researcher was 
available to resolve any differences through discussion.  
        
Risk of bias assessment in individual studies 
 
A risk of bias assessment was performed for each study by one reviewer. The National 
Heart, Lung and Blood Institute (NHLBI) tool was used to assess the clarity and rigour 
of the outcomes/measures, sample recruitment, data collection and statistical analysis 
process of quantitative studies that were cohort/cross sectional in design.  Critical 
Appraisal Skills Programme (CASP) checklists were used to assess the clarity and 
rigour of the recruitment strategy, data collection/analysis methodology, ethical 
considerations and presentation of findings of qualitative studies.  The primary 
strengths and limitations of the methodologies of the papers are summarised in the 
findings section.      
 
Data collection process and data items collected  
 
Data from the studies included in the analysis were extracted by one reviewer onto a 
structured data extraction template.  The following variables were extracted: authors, 
title, year published, study aim, data collection period, study design, study location, 
setting, data collection/analysis methodology and variables of interest as defined in 
table 1.   
 
Data analysis  
 
The narrative approach to synthesis uses words and text to ‘tell the story’ of the 
findings. Popay et al’s (2006) four stage framework and techniques are used to 
increase the transparency and trustworthiness of the narrative synthesis.  The 
literature in this review is used to understand a behavioural event and Table 1 provides 
an initial theoretical model of that behavioural event. The ABC framework is utilised to 
organise and compare evidence and was subject to alterations and refinements as 




Study selection  
 
The number of studies identified, reviewed and selected with reasons for exclusion 
are summarised in Fig 1. The initial total number of articles captured from the search 
was 3438, which after removing duplicates was 2653.  On reviewing article titles there 
were 2362 excluded which left 291 articles for abstract screening.   Eighty articles met 
final inclusion and at full reading there were forty-two excluded, one was not English 
language, five did not fully published primary research data and 36 were not explicitly 
on chemsex drug use which is before or during a sexual encounter. Ten articles (5 
UK: two data sets, 2 Canadian: one data set, 3 Australia: one data set) were based on 
data from four samples but had been used for different study objectives.  A final total 
of 38 articles were included the review.    
 
 

































Study selection and characteristics 
 
Table 3 provides a summary on the aim, population, country, sample size, year of data 
collection, study design and ABC key findings of the 38 articles included in the review.  
The findings section will be presented in the ABC headings but structured as, 1: 
behavior, 2: antecedents, 3: consequences.  Fig.2 provides a summary of the review’s 
main findings which is structured using the ABC framework.  The sample size from all 
the studies ranged from 14 to 6757 participants with data collected from 2001 to 2017.  
The majority of the studies are from the North Americas (13- USA, 2- Canada) or 
Europe (10- UK, 1- Republic of Ireland (ROI), 1- European wide, 1- UK and ROI, 
excluding England, 1- Germany, 3- Netherlands) and only six are from outside these 
areas, which includes five from Australia and one from Israel.  The majority of the 
studies are quantitative cross-sectional studies (26) or qualitative studies (9) with two 
retrospective case note reviews and one observational cohort study.  Thirty-one 
studies reported HIV prevalence rates ranging from 1% to 80%.  Only four studies 
exclusively focused on HIV negative MSM and three studies did not report HIV 
prevalence rates in their sample.  The diverse nature of the samples may explain the 
Studies included in 
synthesis 
(n= 38) 





27: not fully published primary 
research 
6: HIV positive sample  
178: chemsex drug usage not 
before or during sex 




Record titles screened 
(n= 2653) 
Records after duplicates removed 
(n= 2653) 
Additional records identified through 
other sources 
(n = 0) 
Records identified through 
database searching 
(n= 3438)    
9 
Full-text articles excluded, with 
reasons 
(n= 42) 
1: non- English language 
5: not fully published peer 
primary research 
36: chemsex drug usage not 
before or during sex  
wide variations in HIV prevalence.   Some studies specifically recruited MSM engaged 
in chemsex whilst others tried to recruit representative samples of MSM.  There was 
also variation in chemsex prevalence estimates, which may be accounted for by the 
different settings in which studies were conducted. For example, recruitment using 
multiple digital media platforms and participants recruited from specific clinical 
services.  
 


















* the overall prevalence %’s for chemsex engagement incorporates higher level estimates of samples 
from sexual health clinics 
** the overall prevalence %’s for injecting incorporates higher level estimates of samples from drug 
services 
 
Risk of bias assessment in individual studies  
 
The NHLBI tool grades all the quantitative cross-sectional and case note review 
studies as ‘fair’ in terms of their quality. All these studies were rated at this level due 
to limitations in this design which only provided a ‘snapshot’ at one point in time. Most 
of these studies did not provide a sample size justification, only measured the 
exposures once and it is unclear if the researchers were blinded to the status of the 
sample. The primary strengths in most of these studies were the clear objectives, a 
defined sample being recruited, defined exposures/outcomes and appropriate 
methodology for data analysis.  The majority of the qualitative studies provided a clear 
recruitment strategy, justified the data collection methods, secured ethics approval, 
described a rigorous analysis methodology and provided the findings in a clearly 
structured format.  Although the studies briefly discussed key ethics considerations, 
most of them did not critically examine the role between the researcher or sample. 
There was limited discussion of the wider ethics issues raised in or from the study.              
 
Prevalence and type of non-injecting drugs  
 
Ten articles examined the prevalence of chemsex drugs within general MSM samples 
and most of the articles are from the USA and Western Europe (Koblin et al, 2007; 
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Potential impact on 
mental health 
Potential impact on 
social functioning 
2014; Benotsch et al, 2012; Frankis et al, 2018, Rosinska et al, 2018, Hammoud et al 
2018a; Hammoud et al, 2018b).  The majority of the studies each examined numerous 
sex related drugs but two from the USA specifically focused on two stimulants 
(methamphetamine and cocaine) (Koblin et al, 2007, Benotsch et al, 2012).   
 
Eight studies provided an overall prevalence for chemsex related behaviour which 
incorporates various drugs, this ranges from 3%-29% (McCarty-Caplan et al, 2014; 
Hegazi et al, 2017; Rosinska et al, 2018; Druckler et al, 2018; Pakianathan et al, 2018; 
Glynn et al, 2018; Frankis et al, 2018; Hammoud et al, 2018b). Prevalence estimates 
which range from 17%-27% were all of MSM attending sexual health clinics and the 
29% estimate is from an online survey which only used one MSM geo-social dating 
app to recruit the sample (Glynn et al, 2018; Hegazi et al, 2017; Druckler et al, 2018; 
Pakianathan et al, 2018; Hammoud et al, 2018b).  The four other studies provided 
estimates between 3%-13% but they used a wider selection of online platforms to 
recruit MSM samples (McCarty-Caplan et al, 2014; Frankis et al, 2018; Rosinska et al, 
2018, Hammoud et al, 2018b).  Rosinska et al (2018) conducted an online survey of 
MSM across thirteen different European cities which provided a prevalence range of 
between 0%-14%.  Chemsex prevalence varies widely across different countries but 
the evidence is limited with most of samples being recruited from cities or sexual health 
clinics.   
 
Six studies provided use rates for the three drugs primarily connected to chemsex 
(methamphetamine, mephedrone, GHB/GBL) (Frankis et al, 2018; Druckler et al, 
2018; Pakianathan et al, 2018; Glynn et al, 2018; Hegazi et al, 2017; Melendez-Torres, 
2016).  All studies were from Western Europe and the majority recruited MSM samples 
from sexual health clinics.  Mephedrone was the most commonly used in two UK 
studies and the least used in three other three studies from the UK, ROI and the 
Netherlands (Pakianathan et al. 2018; Frankis, 2018; Druckler et al, 2018; Hegazi et 
al 2018; Melendez-Torres et al, 2016, Glynn et al, 2018). Seven studies specifically 
examined rates of GHB/GBL use.  In five studies GHB/GBL was the most commonly 
used chemsex drug but in two other studies it was the second mostly commonly used 
(Hegazi et al, 2017; Melendez-Torres et al, 2016; Heiligenberg et al, 2012, Frankis et 
al, 2018, Druckler et al, 2018; Pakianathan et al. 2018; Glynn et al, 2018).  A study 
from Australia which only examined the use of GHB/GBL reported that 5% of the MSM 
sample had used the drug in the previous 6 months (Hammoud et al, 2018a).  With 
the exception of this study, all the other studies that examined GHB/GBL were from 
Western Europe.  The five studies which suggested that GHB/GBL was the most 
commonly used drug originate from the Netherlands, UK and Ireland and most of the 
samples were recruited from sexual health clinics.   
 
Eight studies examined the use of methamphetamines, in which five provided 
prevalence estimates ranging from 3%-22%.  From these studies the three USA 
(2007-12) stimulant focused articles reported a prevalence range of 9%-22% (Koblin 
et al, 2007; Mor et al, 2008; Ober et al, 2009; Benotsch et al, 2012; Heiligenberg et al, 
2012).  The highest rate of 22% was from the study by Ober et al (2009), which 
consists of MSM with a low income and high rates of previous homelessness. With the 
exemption of this study, the methamphetamine prevalence range was from 3%-10%.   
McCarty-Caplan (2014) in the Chicago study reported an overall chemsex related 
behaviour prevalence rate of 10% which is comparable to the prevalence results of 
the two USA methamphetamine studies of 9%-10%. (Koblin et al, 2007; Benotsch et 
al, 2012).  Six of eight studies that examined the use of various substances all 
identified that methamphetamine was among the highest three most commonly used 
chemsex drugs (Mor et al, 2008; Hegazi et al, 2017; Melendez-Torres et al, 2016; 
Heiligenberg et al, 2012; Frankis et al, 2018, Druckler et al, 2018; Pakianathan et al. 
2018;).     
 
The use of cocaine was examined in seven studies and ketamine within six studies. 
Three of the studies related to cocaine provided prevalence estimates ranging from 
2%-33% (Mor et al, 2008; Ober et al, 2009; Heiligenberg et al, 2012).  The highest rate 
of 33% was from the Ober et al study and with the exception of this study the cocaine 
estimates range from 2%-15%.  Four of the studies which examined the use of varying 
chemsex drugs indicated that cocaine was one of the least used drugs (Mor et al, 
2008; Hegazi et al, 2017; Melendez-Torres et al, 2016; Pakianathan et al. 2018). Two 
of the studies related to ketamine reported a prevalence ranging from 1%-4% and four 
studies ranked ketamine as one of the least used chemsex drugs (Mor et al, 2008; 
Heiligenberg et al, 2012; Hegazi et al, 2017; Frankis et al, 2018; Pakianathan et al. 
2018).  Only two studies from the Netherlands and ROI found ketamine was used 
more frequently than methamphetamine (Heiligenberg et al, 2012; Glynn et al, 2018).   
 
Prevalence and type of injecting drugs   
 
Nine of the studies examined MSM injecting drug use for sexual purposes which 
provided prevalence estimates ranging from 1%-50% (Gilbart et al, 2015; Hopwood et 
al, 2015; Bowden-Jones, 2017; Hegazi et al, 2017; Ahmed et al, 2017; Bui et al, 2018; 
Frankis et al, 2018; Druckler et al, 2018; Glynn et al, 2018).  Five studies which 
examined this in large MSM samples reported a prevalence range of 1%-9% and 
within three of the studies methamphetamine was the most commonly injected drug 
(Hopwood et al, 2015, Frankis et al, 2018; Glynn et al, 2018; Druckler et al, 2018; Bui 
et al, 2018).  The remaining four studies targeted specific MSM populations or had 
small MSM samples which reported a prevalence range of 25%-50%.  These studies 
may have reported higher rates of injecting because two-focused on chemsex users, 
one was a small sample diagnosed with shigella and another was a small sample from 
sexual health clinics. Only one of these studies specified drug types, which indicates 
that most chemsex injectors primarily use methamphetamine (Bowden-Jones, 2017).   
 
Four studies reported a wide variation in the levels of sharing injecting equipment 
which ranges from 5%-56%, although the three most recent studies reported a range 
of 5%-12% (Hegazi et al, 2017; Hopwood et al, 2015; Bowden-Jones et al, 2017; Bui 
et al, 2018).  Gilbart et al (2015) highlighted that their study sample had a low level of 
knowledge related to the risks of BBV transmission. Only one study from Australia 
identified that the injecting of drugs was associated with multiple partners and group 
sex (Bui et al, 2018).  From the evidence it appears methamphetamine is the most 
commonly injected drug and there are variations in the extent to which users adopt 
safe injecting practices.  However, there are limitations in determining injecting 
prevalence and associated risk behaviours due to the heterogeneous nature of the 





Drug Use Setting  
 
Thirteen of the studies examined elements of the environments and related drug use 
patterns linked to chemsex related behaviors (Ober et al, 2009; Prestage et al, 2009; 
Grov et al, 2013; Bourne et al, 2015; Rich et al, 2016a; Rich et al, 2016b; Gilbart et al, 
2015; Deimel et al, 2016; Melendez-Torres et al, 2016; Ahmed et al, 2017, Melendez-
Torres, 2017; Rusow et al, 2017, Bowden-Jones, 2017).  Most of these studies 
involved specific samples of MSM; five focused on varying elements of drug using 
MSM and three on MSM who engaged in group sex or multi-partner sexual 
encounters. All the studies indicated that there was a complex two-way interface 
between MSM using specific drug types to facilitate multi-partner sexual events, within 
which the venue plays an integral role.  
 
Five studies showed that chemsex related activities primarily occured in sex on 
premise venues (SPV) (bath houses/saunas) or private homes (Ober et al, 2009; 
Bourne et al, 2015; Rusow et al, 2017; Ahmed et al, 2017; Melendez-Torres, 2016;).  
Two studies highlighted that between 22%-38% of encounters took place in SPVs and 
52%-66% within private homes (Melendez-Torres, 2016; Ober et al, 2009).  Two UK 
studies highlighted that with the growth in MSM using geo-social networking platforms, 
there is potentially a change in chemsex being more likely to occur in private homes 
(Ahmed et al, 2017; Bourne et al, 2015).  Three studies from Western Europe reported 
that chemsex based sex parties mostly involved multiple casual partners and can last 
from a few hours to several days (Deimel et al, 2016; Gilbart et al, 2015; Bourne et al, 
2015).        
 
Prestage et al (2009) reported that 63% of an MSM group sex attendee sample had 
consumed illicit drugs at a group sex event in the previous six months.  In comparison, 
a more recent study from a UK club drug clinic highlighted that 75% of the MSM 
sample had used the primary chemsex related drugs (mephedrone, 
methamphetamine, GHB/GBL) to facilitate sex (Bowden-Jones et al, 2017).  Three 
studies indicated that consumption of varying stimulants occured at group sex events, 
which could include methamphetamine, GHB/GBL, mephedrone, ecstacy, cocaine 
and ketamine (Grov et al, 2013; Rich et al, 2016a; Prestage et al, 2009).  Three studies 
reported that between 14%-26% of MSM attending sex parties consumed erectile 
disorder drugs (EDDs) and within two studies EDDs were more likely to be associated 
with methamphetamine use (Gilbart et al, 2015; Melendez-Torres, 2016; Prestage et 
al, 2009). Gilbart et al (2015) found MSM chemsex participants were more likely to 
use EDDs to counteract the physiological effect of methamphetamine.          
 
Sexual behaviour  
 
Seventeen studies identified that there can be an increased risk of condomless anal 
intercourse (CAI) when chemsex drugs were combined with sex (Koblin et al, 2007; 
Ober et al, 2009; Prestage et al, 2009; Benotsch et al, 2012; McCarty-Caplan, 2014; 
Melendez-Torres, 2016; Ottaway et al, 2017; Melendez-Torres et al, 2017; Gilbart et 
al, 2015; Bourne et al, 2015; Ahmed et al, 2017, Reback et al,2018; Glynn et al, 2018; 
Druckler et al, 2018, Hoornenborg et al, 2018; Frankis et al, 2018).  Only three studies, 
with specific and limited samples, provided rates of CAI which are explicitly when 
chemsex drugs are combined with sex, which ranges from 30%-38% (Ober et al, 2009; 
Bourne et al, 2015; Melendez-Torres et al, 2016).  Five UK studies identified that when 
the sexual encounter involved chemsex dugs there was a higher likelihood of men 
performing esoteric sex acts (for example: fisting) (Hegazi et al, 2017; Ahmed et al, 
2017; Gilbart et al, 2015; Frankis et al, 2018; Pakianathan et al. 2018).  Two of these 
studies had high rates of HIV positive men in the sample and one study had a small 
sample of men diagnosed with shigella.       
 
Six of the studies examined the associations between specific drug types and the 
likelihood of engaging in high risk sexual activity.  All of these studies found that 
methamphetamine use with sex was associated with CAI but only one study found this 
was distinctly with HIV negative sex partners (Koblin et al, 2007; Ober et al, 2009; 
Prestage et al, 2009; Benotsch et al, 2012; Melendez-Torres et al, 2016; Reback et 
al, 2018). One of these studies found there was an interconnection between the use 
of methamphetamine and EDDs with sex, which increased levels of CAI (Melendez-
Torres et al, 2016).  Evidence for other specific drugs was limited but this may be due 
to studies focusing on methamphetamine use.                
 
Bio-medical risk reduction interventions 
 
Ten studies examined elements of STI/BBV testing, post-exposure prophylaxis (PEP), 
PrEP and injecting equipment provision (IEP) services (Prestage et al, 2009; Gilbart 
et al, 2015; Hopwood et al, 2015; Hegazi et al, 2017; Pakianathan et al. 2018, Frankis 
et al 2018; Druckler et al, 2018; Hammoud et al, 2018a; Hammoud et al, 2018b; 
Closson et al, 2018).  One Australian study highlighted that 89% of the sample had 
ever had an HIV test and a more recent UK study identified that 94% of the sample 
had ever attended sexual health services (Prestage et al, 2009; Gilbart et al, 2015).  
However, the UK study is unlikely to be representative as 63% of the sample were HIV 
positive.  Hopwood et al (2015) identified that in the previous 12 months 72% of the 
HIV negative men had tested for HIV and 77% of the HCV negative men had tested 
for HCV.  A recent study from Western Europe identified that the likelihood of engaging 
in chemsex is greater if MSM have had an HIV test in the previous 3 months (Frankis 
et al, 2018).   
 
Two studies identified that chemsex participants were more likely to access PEP than 
non-chemsex participants.  (Hegazi et al, 2017; Pakianathan et al. 2018). An 
Australian study reported that 80% of the PrEP users had not engaged in chemsex in 
the previous 6 months, although this was a relatively small sample and 16% did not 
answer the chemsex question (Hammoud et al, 2018b). However, a Netherlands study 
highlighted that MSM who engaged in chemsex were more likely to be on PrEP than 
MSM who did not participate in the activity (Druckler et al, 2018).  A study which 
explored MSM chemsex participants’ views of PrEP highlighted that more regular drug 
users would prefer daily dosing and less frequent drug users would opt for episodic 
dosing (Closson et al, 2018).  Gilbart et al (2015) identified that most MSM who 
injected chemsex drugs were generally unaware of injecting equipment service 
provision and safer injecting practices.  However, this study had a small sample 
diagnosed with shigella.  Based on this evidence it is difficult to conclude how MSM 





Socio-demographics of participants 
 
Thirteen studies examined elements of key socio-demographics of MSM samples that 
used chemsex related drugs before or during sex and the majority of the studies are 
from the USA and UK.  Eight studies provided a mean or median age for chemsex 
participants, ranging from 32 to 42 (Green & Halkitis, 2006; Weatherburn et al, 2016; 
Hegazi et al, 2017; Benotsch et al, 2012; Reback et al, 2018; Druckler et al, 2018; 
Rosinska et al, 2018; Closson et al, 2018) and one study into chemsex injectors 
reported a median age of 42 (Hopwood et al, 2015).  Frankis et al (2018) identified 
that MSM between the ages of 36-45 were more likely to engage in chemsex.  In the 
six studies that reported sexual identity, the majority of the sample identify as gay 
(Green and Halkitis, 2006; Benotsch et al, 2012; Hopwood et al, 2015; Weatherburn 
et al, 2016; Reback et al, 2018; Closson et al, 2018) and in six of the seven studies 
that reported ethnicity, most of the sample identified as white (Green and Halkitis, 
2006; Benotsch et al, 2012; Weatherburn et al, 2016; McCarty-Caplan, 2014; Druckler 
et al 2018; Closson et al, 2018).     
 
Rusow et al (2017) found in a USA study that MSM who combined methamphetamine 
with sex were significantly more likely to be white and identify as being gay. In another 
USA study, methamphetamine had higher rates of use in white and Hispanic 
populations’, but they were less likely to use cocaine when compared to black MSM 
(Ober et al, 2009).  In comparison, a USA study reported that white MSM used less 
cocaine with sex compared to ethnic groups (Reback, 2018), but this study may be 
limited by the small number of white MSM in the sample.  From this limited evidence 
it is not clear if ethnicity is a determining factor for engaging in chemsex.  Two studies 
identified that chemsex participants spend most of their time with other gay men but 
does not necessarily mean that most of their social network consists of friends who 
were gay men (Kelly et al, 2012; Hopwood et al, 2015).  It appears from the overall 
evidence that chemsex participants were more likely to be a gay man and participation 
peaks between the mid-thirties to early forties but is evident at all ages.          
 
Role of HIV status  
 
Eleven studies identified that HIV positive MSM were more likely to use chemsex 
drugs with sex, when compared to MSM of non-HIV positive status (Ober et al, 2009; 
McCarty-Caplan, 2014; Rich et al, 2016b; Gilbart et al, 2015; Hegazi et al, 2017; 
Bowden-Jones et al, 2017; Rusow et al, 2017; Frankis et al, 2018; Rosinska et al, 
2018; Hammoud et al, 2018a; Pakianathan et al. 2018).  Only one study provided an 
analysis on the role of HIV status in injecting drug use, which found HIV positive status 
was associated with recent injecting and sharing of injecting equipment (Bowden-
Jones et al, 2017).  In comparison, a study on injecting drug use reported recent 
injectors were significantly more likely to be HIV positive when compared to other 
study participants (Bui et al, 2018).  Due to the limited evidence it is not possible to 
substantively conclude what role HIV plays in the injection of drugs for sexual 
purposes.  
 
Four studies reported that within chemsex related behaviour HIV positive MSM were 
more likely to sero-sort and engage in CAI with HIV positive partners (Gilbart et al, 
2015; Bourne et al, 2015; Melendez-Torres et al, 2016; Rich et al, 2016a).  One study 
found that there was less incidence of CAI at sexual encounters when partner HIV 
status was sero-discordant or unknown (Melendez-Torres et al, 2017).  The evidence 
indicates HIV status is potentially an important factor in determining if men that engage 
in chemsex use condoms.         
 
Expectations of the event 
 
Twelve articles indicated that MSM who engage in chemsex related behaviors may 
have perceptions and expectations that the desired physiological effects of a drug will 
alter a sexual event (Kurtz, 2005; Green and Halkitis, 2006; Kubicek et al, 2007; 
Jerome et al, 2009; Benotsch et al, 2012; Bourne et al, 2015; Deimel et al, 2016; 
Weatherburn et al, 2016; Ahmed et al, 2017; Prestage et al, 2009;  Bui et al, 2018; 
Hammoud et al, 2018a).  These studies were primarily qualitative and from the UK 
and USA.  There were variable and multi-faceted effects when chemsex drugs were 
combined with sex, but these can be categorised into primary domains. The findings 
from the articles can be themed into physical, mental, emotional and social domains.  
Fig 3. provides a summary of drug effects and the potential desired outcomes that 
alter the sexual event.      
 
Most of the studies found that a key effect is the ability to increase stamina and arousal 
levels, so an individual can engage in sex for sustained periods and facilitate easier 
receptive anal intercourse/sex acts (Kurtz, 2005; Green and Halkitis, 2006; Kubicek et 
al, 2006; Jerome et al, 2009; Bourne et al,2015; Deimel et al, 2016; Ahmed et al, 2017; 
Weatherburn et al, 2016; Prestage et al, 2009; Bui et al, 2018; Hammoud et al, 2018a).  
Some of the studies reported that the reduction in cognitive inhibition allowed the men 
to overcome under confidence and enhanced their ability to engage more meaningfully 
with sex partners (Green and Halkitis, 2006; Jerome et al, 2009; Weatherburn et al, 
2016).  The lowering of inhibitions may be important in establishing more immediate 
and sustained interaction with sex partners, providing a more meaningful shared 
sexual experience.  Some of the studies identified that the increase in awareness and 
intensity of feeling was important for men to enhance their emotional connection with 
partners during sex (Green and Halkitis, 2006; Jerome et al, 2009; Weatherburn et al, 
2016).  There are interactions between all these domains with an overarching theme 
being to maximise the intensity of a sexual event.        
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Biological Impact  
 
As indicated earlier, HIV positive men are potentially more likely to engage in high risk 
chemsex related behaviours.  However, it is important to recognise that a significant 
number of HIV negative MSM may engage in chemsex and be at risk of HIV.  Seven 
studies that had a majority of drug users in their samples, reported an assumed HIV 
negative prevalence range of 20% to 59% (Kurtz et al, 2005, Green and Halkitis, 2006; 
Bourne et al, 2015; Hopwood et al, 2015; Bowden Jones et al, 2017; Deimel et al, 
2016; Reback et al, 2018).  From the earlier evidence, it is apparent that when drugs 
are combined with sex that there is an increased risk of men engaging in CAI. An 
important variable for rates of CAI is the effect of drugs.  A few studies identified that 
drugs effect decision making during sex, which can influence a participant’s choice to 
engage in high risk sexual practices (Bourne et al, 2105; Gilbart et al, 2015; Ahmed et 
al, 2017; Deimel et al, 2016).  These interconnected factors demonstrate that HIV 
negative MSM who engage in chemsex related behaviours are potentially at increased 
risk of disease transmission.   
 
Four studies examined levels of HCV in chemsex related behaviour which identified a 
prevalence range of 6%-30% and two of these studies report an HIV/HCV co-infection 
prevalence range of 9%-21% (Hopwood et al, 2015; Bowden-Jones, 2017; Deimel et 
al, 2016; Bui et al, 2018).  The highest rate of 30% was from a study with a small 
sample size of which approximately 80% were HIV positive. Three of the studies with 
the highest prevalence rates had samples which primarily consisted of men who 
injected drugs.  Bui et al (2018) identified that recent injectors were more likely to be 
HCV positive compared to non-recent injectors.  There was limited evidence to 
indicate HCV infection rates among MSM who inject chemsex drugs.    
 
All seven studies that examined components of STIs identified that MSM who engage 
in chemsex related behaviours have had issues with previous infections (Ottaway et 
al, 2017; Hegazi et al, 2017; Gilbart et al, 2015; Kurtz, 2005, Druckler et al, 2018; 
Rosinska et al, 2018; Glynn et al, 2018).  One of the studies identified that MSM 
diagnosed with STIs were more likely to engage in chemsex (Ottaway et al, 2017).  In 
comparison, four studies identified that chemsex participation was associated with the 
diagnosis or treatment of an STI (Hegazi et al, 2017, Rosinska et al, 2018; Druckler, 
2018; Glynn et al, 2018).  Ottaway et al (2017) identified that those diagnosed with an 
STI were more likely to engage in chemsex, were more likely to be HIV positive and 
have higher rates of CAI.  The studies indicated that MSM who engage in chemsex 
are potentially at a high risk of STI transmission.   
 
Psycho-social impact  
 
Six studies examined aspects on the perceived and actual psychological and social 
consequences of chemsex related behaviours.  A recent study highlighted that 25% 
of the MSM sample reported that chemsex had a negative effect on their lives (Glynn 
et al, 2018).  Two USA studies highlighted that there is a perception that 
methamphetamine will have negative consequence on social networks, with the loss 
of friends & partners (Kurtz, 2005; Kubicek et al, 2007).  A USA study highlighted that 
methamphetamine users reported that sustained use of the drug reduced their ability 
to fulfil daily functioning (Closson et al, 2018).  In comparison, an Australian study 
identified that the higher the use of GHB reported by the sample, the greater the impact 
on the drug user’s social networks (Hammoud et al, 2018a).  Two studies identified 
that chemsex drug use can have an impact upon employment, within one study some 
men had lost their jobs and in the other study 14% of the men had taken time off work 
(Kurtz, 2005; Hegazi et al, 2017).  One UK study identified that 15% of the sample 
reported chemsex participation had a negative impact on their mental health and a 
USA study identified some methamphetamine users experience issues with paranoia 
(Hegazi et al, 2017; Kurtz, 2005).  In comparison, another study reported that poly 
drug users were more likely to experience psychological distress when compared to 
sexualised drug users, but this did not attain statistical significance (McCarty-Caplan, 
2014). A study on GHB did not find that the drug use was associated with depression 
or anxiety (Hammoud et al 2018a).  There is limited evidence that fully explores the 
psycho-social impact, although some of the men in the studies had experienced 




To our knowledge, this is the first systematic review on chemsex behaviour to 
exclusively incorporate and examine research on chemsex drug use before or during 
sex.  Two literature reviews (Edmundson et al, 2018: UK research; Tomkins et al, 
2018: research from every country) have examined the wider issue of sexualised drug 
usage among MSM; but did not provide an in-depth analysis of the behaviours 
involved in the sexualised setting of chemsex drug use.  In early 2018 two special 
journal editions on chemsex were published but the two previous literature reviews did 
not fully incorporate this research.  As such, this is the first comprehensive up to date 
review of chemsex behaviour which examines participants socio-demographics, 
expectations of the event, prevalence estimates, high risk behaviours and the 
biopsychosocial consequences.   
          
This review used the ABC framework as a model to structure the results and 
conceptualise the behavioural processes involved in chemsex.  The key advantage of 
this approach was the ability to process a complex array of research into an 
understandable three stage behavioural event.  Expectations of the event are a 
fundamental antecedent that influences MSM who engage in chemsex.  MSM that 
engage in chemsex behaviour expect that drugs may trigger multiple effects on the 
body that will facilitate, enhance, prolong and sustain a sexual event. Participants may 
seek a drug’s desirable effects, but the disinhibiting effects may increase the level of 
risk taking behaviour which subsequently may produce undesirable consequences.  
HIV is a key influencer through the whole ABC process as HV status can influence the 
likelihood of engagement in chemsex, effect the event behaviour and HIV transmission 
can be a potential consequence.   
 
In the wider literature there are large variations in the prevalence estimates for 
chemsex.  The review published by Tomkins et al (2018) identified a prevalence range 
from 4%-94%, but it incorporates research that does not fit within the PHE definition 
of chemsex.  Edmundson et al (2018) identified that chemsex drugs were also used 
outside of sexual events and the inter-changeable use of sexualised drug usage and 
chemsex can cause ambiguity in estimating prevalence levels.  Edmundson et al 
(2018) identified one study with an overall prevalence of 17% and the review identified 
a range of 3%-29%. However, the majority of prevalence estimates in this review 
above 15% are based on samples from sexual health clinics.  The overall research 
indicates that the prevalence of chemsex varies in different countries but also varies 
within different regions/cities within one country.   
 
It is evident from the findings that there are varying types of drugs used in chemsex 
behaviours, which can vary by geographical location.  The prevalence estimates for 
methamphetamine were published over a longer-time frame and includes research 
from different continents (Europe, North America, Australia).  This may be explained 
by the MSM population having a longer history of using this drug.   Research 
examining mephedrone and GHB/GBL was primarily from Western Europe, with the 
exception of one recent study on GHB/GBL from Australia.  It is not possible to 
evidence specific changes in drug trend’s, although type of drug use varies across 
different high-income regions/countries.  As chemsex is a socially constructed 
phenomenon the use of specific drugs will vary across different cultures and MSM 
sub-populations.  This limits the generalisability of findings which is reflected in the 
different studies consisting of greatly varied types of sample. The social constructed 
nature of chemsex accounts for the variation in prevalence estimates and types of 
drug used across the different geographical areas.  
 
This review highlights that MSM who combine chemsex drugs with sex are engaging 
in high risk sexual behaviours, including CAI and esoteric acts.  There is a lack of 
knowledge on the specific rates of CAI that occur during chemsex, but it is evident that 
behaviour is mediated by participants HIV status.  There is substantive evidence in 
this review to demonstrate that some HIV negative MSM who participate in chemsex 
will engage in CAI.  The Edmundson et al (2018) review concluded that engagement 
in sexualised drug use can lead to CAI.  This correlates with the review’s findings 
which suggests that MSM who combine drugs with sex are more likely to engage in 
high risk sexual practices when compared to MSM who do not combine drugs with 
sex.  
 
The studies from Western Europe and Australia which analysed the injection of drugs 
provided varied prevalence estimates for injecting drugs (1%-50%) for sexual 
purposes and for the sharing of injecting equipment (5%-56%).  This may be 
accounted for by some studies using general samples and others recruiting smaller 
samples from high risk groups.  A longitudinal analysis of MSM injecting drug use in 
Australia reported that between 5%-6% of the sample had injected in the previous 6 
months (Lea et al, 2013).  Edmundson et al (2018) identified that over a 15-year period 
the number of MSM attending UK drug services reporting injecting drug use had nearly 
doubled (4% to 8%) and there was a growth in the use of stimulants.  However, it is 
important to highlight that the data within these publications did not exclusively focus 
on injecting for sexual purposes.  The evidence shows that a small minority of the 
wider MSM population inject drugs but there is a lack of research examining MSM 
sexualised injecting of drugs.   
 
This review indicates that high risk chemsex behaviours puts participants at increased 
risk of acquiring STIs/HIV and there is limited evidence that suggests there are 
psycho-social consequences.  However, the majority of the evidence base regarding 
the risk of STIs and HIV is associative.  There is also a lack of research which 
exclusively focused on the behaviour of HIV negative MSM and the associated 
consequences. The findings in this review supports work by Tomkins et al (2018) who 
reported that chemsex behaviour has a negative impact on some participants social 
functioning and mental well-being.  However, Prestage et al (2018) identified that drug 
use during sexual activity was not associated with depression. The study did identify 
that illicit drug use is associated with depression and anxiety when the use becomes 
problematic or dependent (Prestage et al, 2018).  The earlier findings in the review 
indicates that between 14%-25% of chemsex participants have experienced a 
negative impact on their psycho-social functioning. The wider literature provides 
evidence which demonstrates that the higher the frequency of the drug use, the more 
detrimental the impact is on psycho-social well-being of the user, particularly if they 
engage in poly-drug use (Ives and Ghelani, 2009; European Monitoring Centre for 
Drugs and Drug Addiction, 2009). There is also the biological risk for poly-drug users 
who use different substances which can create highly toxic and dangerous reactions 
in the body.  However, evidence for the impact of chemsex behaviours on psycho-
social well-being is weak although it is anticipated that the potential consequences for 
frequent poly-drug users are significant. 
   
The studies in the review that examined the use of STI/BBV screening, PEP and PrEP 
use did not provide substantive answers on how commonly chemsex participants use 
these interventions.  The limited evidence indicates that a majority may either access 
screening or attend sexual health services but does not provide a clear understanding 
on frequency and type of testing.  However, the recent publication from Frankis et al 
(2018) indicated that chemsex engagement is associated with men who had an HIV 
test in the previous three months.  There is very limited evidence which suggests 
chemsex participants are more likely to access PEP and PrEP compared to MSM who 
do not engage in chemsex.  However, it is possible that greater access to PrEP/PEP 
by chemsex participants is influenced by service providers.  Sewell et al (2017) 
identified in a study of MSM chemsex drug users that the level of PEP use was 14% 
and PrEP use was 4.5%.   
 
A clinical trial of PrEP reported that in the previous three months approximately 44% 
of the MSM sample had used methamphetamine, GHB/GBL or mephedrone (Dolling 
et al, 2016).  In comparison, a recent study from Australia highlighted that the 
concurrent use of methamphetamine, EDDs and PrEP in 2014 was 1.9% but this 
increased to 6% in 2017 (Hammoud et al, 2018b).  However, the paper by Hammoud 
et al (2018b) does not directly link the chemsex drug use episodes to PrEP use (Gafos 
et al, 2018).  The overall evidence indicates that PrEP is being used by some MSM 
who use chemsex drugs, but the majority of previous research does not identify if the 
drug usage is within a sexual setting.  As PrEP is a relatively new innovation it is 
important to understand how chemsex participants use the range of bio-medical 
interventions.  This remains an important research question as the introduction of 
PrEP could potentially influence how chemsex participants use other interventions and 
chemsex behaviours may influence the participants PrEP adherence.     
 
This review adopted a precise and clear systematic methodology to address it’s 
objectives.  A strength is the explicit inclusion/exclusion criteria which focused on the 
use of chemsex drugs before or during sex.  However, is not able to determine if the 
sexual activity was planned.  The review is limited by the absence of clear sampling 
frames in the published studies and the resulting heterogeneity of predominantly 
purposive samples across the studies. The review may also be limited by its exclusion 
of research from low to medium income countries and by including only English 
language articles.  
 
To enable improved future research into chemsex it may be beneficial to develop 
standardised questioning that identifies if chemsex drug use is before or during 
planned sexual activity.  The review has identified some key research gaps and 
recommends future research in the following areas: i) research exclusively on HIV 
negative MSM chemsex behaviours; ii) explore and examine the prevalence and risk 
behaviours of MSM who inject chemsex drugs for sexual purposes; iii) examine MSM 
chemsex participants use of bio-medical interventions, specifically the use of PEP and 
PrEP; and iv) in-depth exploration on the psycho-social impact on MSM who engage 
in chemsex.  These research recommendations reflect components in Fig. 2 and 
relationships between them. The ABC model was a useful conceptual framework in 
the synthesis of the evidence and it’s use would be worth considering to inform future 
work.  Research in these areas could improve the efficiency and targeting of risk 
reduction interventions that reduce the biopsychosocial impact of chemsex 
behaviours.  
 
Conclusion          
        
It appears a minority of MSM engage in chemsex behaviour, but there are inter-
connected high-risk behaviours associated with the activity.  The examination of 
chemsex is limited due to the challenge in defining the activity and there are limitations 
in comparing prevalence estimates due to the use of different sampling frameworks.  
However, there are potentially multiple consequences associated with chemsex 
behaviour although this remains an under researched area.  With the increasing 
availability of PrEP, it is important to understand how bio-medical interventions can be 
effectively used to reduce the potential impact of high risk chemsex behaviours among 
this population.   
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